luspatercept-aamt (Reblozyl)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • 1 mg/kg SC every 3 weeks

Injection: 75 mg lyophilized powder in a single-dose vial

Adverse effects

Mechanism of action

More general terms

References

  1. RxNorm
  2. FDA Drug Approval. Nov 8m 2019 FDA approves luspatercept-aamt for anemia in patients with beta thalassemia. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-patients-beta-thalassemia
  3. 3.0 3.1 European Society of Medical Oncology Myelodysplastic Syndromes Clinical Practice Guidelines (ESMO, 2021) Medscape - Feb 03, 2021. https://reference.medscape.com/viewarticle/944879
  4. Highlights of Prescribing Information. REBLOZYL (luspatercept-aamt) for injection, for subcutaneous use https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf